Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are currently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last year is $76.50.

Several research analysts have recently issued reports on GPCR shares. William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $21.13 on Friday. The stock's fifty day moving average is $22.00 and its 200 day moving average is $25.00. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $54.08. The firm has a market capitalization of $1.21 billion, a PE ratio of -28.55 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently bought and sold shares of the stock. Zimmer Partners LP increased its holdings in Structure Therapeutics by 77.1% during the 1st quarter. Zimmer Partners LP now owns 100,776 shares of the company's stock worth $1,744,000 after purchasing an additional 43,876 shares during the period. Vestal Point Capital LP increased its holdings in Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after purchasing an additional 63,990 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Structure Therapeutics by 3,326.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock worth $949,000 after purchasing an additional 53,216 shares during the period. Point72 Europe London LLP boosted its position in shares of Structure Therapeutics by 188.7% during the 1st quarter. Point72 Europe London LLP now owns 90,697 shares of the company's stock worth $1,570,000 after acquiring an additional 59,277 shares in the last quarter. Finally, DAFNA Capital Management LLC boosted its position in shares of Structure Therapeutics by 66.2% during the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after acquiring an additional 23,500 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.